Cancer is harder to treat after it spreads but.
First line treatment in metastatic renal cell cancer.
The incidence of renal cell carcinoma rcc has steadily risen over the past 10 years and accounts for 2 3 of all adult malignancies 1 metastatic rcc mrcc is associated with a poor prognosis.
The therapeutic approach for renal cell carcinoma is guided by the probability of cure which i.
Ye d xuechen wang a sumanta k.
Metastatic renal cell carcinoma is cancer in your kidneys that has spread to other parts of your body.
With the advent of targeted therapies many treatment options in the first line setting of metastatic clear cell renal cell carcinoma mccrcc have emerged.
The first 100 words appear below.
A network meta analysis provides an approach for quantitative analysis.
Hahn a zachary klaassen b c neeraj agarwal a benjamin haaland a john esther a xiang y.
No head to head clinical trials compare contemporary first line therapies for metastatic renal cell carcinoma mrcc.
Historically 5 year survival was around 8 but that is rapidly improving 2 for many years the only treatment for mrcc approved by the us food and drug administration fda was high dose interleukin.
Pal e christopher j d.
Guidelines and randomized trial reports usually do not elucidate the decision criteria for the different treatment options.
First line treatment of metastatic renal cell carcinoma.
J clin oncol.
Treatment protocols for renal cell carcinoma are provided below including treatment of localized and advanced disease and recommendations for patients with predominantly clear cell carcinoma and those with predominantly non clear cell carcinoma.
Many recent first line clinical trials for mrcc employed the international metastatic rcc database consortium criteria to aid in risk stratification of patients.
1 however 30 to 40 of patients will develop metastatic disease after definitive treatment of localized disease 2 3 4 although for localized disease surgical resection with curative intent has been the standard approach for metastatic rcc mrcc.
The relatively rapid evolution and rate of approval for metastatic renal cell carcinoma mrcc treatments have created a degree of complexity and ambiguity to first line treatment choice.
Globally the incidence and mortality of renal cell carcinoma rcc has corresponded to 403 000 new cases and 175 000 deaths.
This article has no abstract.
Randomized phase ii trial of first line treatment with sorafenib versus interferon alfa 2a in patients with metastatic renal cell carcinoma.
The treatment of metastatic renal cell carcinoma has been revolutionized twice in the past 12 years by data showing that vascular.
